Genomtec (4VI) Stock Overview
Researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
4VI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Genomtec S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł0.81 |
| 52 Week High | zł2.21 |
| 52 Week Low | zł0.71 |
| Beta | 0.12 |
| 1 Month Change | 5.72% |
| 3 Month Change | -36.39% |
| 1 Year Change | -47.00% |
| 3 Year Change | -64.50% |
| 5 Year Change | n/a |
| Change since IPO | -68.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4VI | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.3% | -2.0% | -2.1% |
| 1Y | -47.0% | -12.4% | 11.4% |
Return vs Industry: 4VI underperformed the German Biotechs industry which returned -11.9% over the past year.
Return vs Market: 4VI underperformed the German Market which returned 13.2% over the past year.
Price Volatility
| 4VI volatility | |
|---|---|
| 4VI Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 12.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 4VI's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4VI's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 26 | Miron Tokarski | www.genomtec.com |
Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company’s flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysis of biological material of patients using swabs, urine, and saliva. It also develops SNAAT chemistry for mutation detection in oncology.
Genomtec S.A. Fundamentals Summary
| 4VI fundamental statistics | |
|---|---|
| Market cap | €13.71m |
| Earnings (TTM) | -€2.61m |
| Revenue (TTM) | €3.55k |
Is 4VI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4VI income statement (TTM) | |
|---|---|
| Revenue | zł15.00k |
| Cost of Revenue | zł8.13m |
| Gross Profit | -zł8.12m |
| Other Expenses | zł2.89m |
| Earnings | -zł11.01m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.73 |
| Gross Margin | -54,113.33% |
| Net Profit Margin | -73,393.33% |
| Debt/Equity Ratio | 4.2% |
How did 4VI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/19 14:25 |
| End of Day Share Price | 2026/01/19 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genomtec S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.